Get access to this article and all of bmj.com for the next 14 days
Sign up for a 14 day free trial today
Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.
Genetic testing is moving from analysis of specific genes to sequencing of the whole genome. Clinical genome-wide sequencing is already offered by a handful of private companies and diagnostic laboratories in the US and by some countries in Europe. In December 2012, the UK prime minister announced ambitious plans to sequence the whole genomes of 100 000 NHS patients over the next three to five years.1 And in July the Department of Health set up Genomics England to help deliver the 100K Genome Project into mainstream healthcare in the NHS, with the initial focus on patients having genetic testing for the diagnosis of rare disorders, cancers, and infectious disease.2 3 4 5 6 Policy makers around the world are currently grappling with how to guide the implementation of genome sequencing in the clinic. Clear testing policy now needs to be agreed that covers issues such as whom to test and how to store, protect, and share genomic data appropriately.